Yafei (Shanghai) Biopharmaceutical Technology

About Yafei (Shanghai) Biopharmaceutical Technology

Yafei (Shanghai) Biopharmaceutical Technology Co., Ltd. operates as a clinical-stage biopharmaceutical company with a focus on developing anti-tumor treatments. Founded on May 30, 2012, the firm is headquartered in Pudong, Shanghai. The company's legal representative is listed as CHENG LIU (刘辰).

The company, also known as Affinity Biopharma, was founded by Dr. Cheng Liu, who serves as the CEO and is a key originator of the company's core technology. Dr. Liu is recognized as a scientist in intelligent drug design, with extensive experience in tumor treatment, immunology, and the role of proteases in the tumor microenvironment. The management team includes Dr. Yuan Liu as Chief Technology Officer, who has over 20 years of experience in protein drug research and development, and Dr. Chris Huang as Co-Chief Medical Officer, with 30 years of experience in international clinical development.

Affinity Biopharma has developed a proprietary Tumor MicroEnvironment Activated (TMEA) drug platform. This technology is designed to selectively release active drugs within the tumor microenvironment, aiming to solve the problem of "on-target/off-tumor toxicity," enhance efficacy at targeted sites, and improve the therapeutic index. The TMEA platform encompasses several specialized sub-platforms, including TMEA-SMDC (Small Molecule-Drug Conjugates), TMEAbody®, TMEAkine®, TMEA-ICE®, ADC (Antibody-Drug Conjugate), and TMEA-XDC. The company's pipeline consists of over 20 innovative drug candidates for treating major diseases like cancer, with its first TMEA SMDC drug having entered a pivotal Phase II/III trial.

The company's business model revolves around the research, development, production, and commercialization of its proprietary drugs. It also engages in strategic partnerships, including out-licensing, co-development, and joint ventures to advance its pipeline and technology platforms. Yafei Biopharma has secured significant funding to support its operations. In late 2024, the company announced the completion of its Series B2 financing round, raising over 400 million CNY. This funding round was led by SDIC Fund Management Co., Ltd. and saw participation from several other investment institutions. The capital is intended to accelerate the clinical research and development of its drug candidates and technology platforms.